Table 2.

Susceptibility of serial passaged HSV-1 SC16 isolates to PCV as measured by the PRA.

Parental SC16a	Passage No.	PCV IC50 (μg/ml)
		Placebo	FCV	VCV
0.39	1	0.36 ± 0.04b	0.42 ± 0.07	0.42 ± 0.05
0.57	2	0.48 ± 0.16	0.76 ± 0.23	0.74 ± 0.35
0.90	3	0.33 ± 0.08	0.50 ± 0.24	0.49 ± 0.36
0.73	4	1.13+0.46	1.31 ± 0.42	2.73 ± 3.11c
0.77	5	1.15 ± 0.24	0.68 ± 0.15	0.68 ± 0.07
0.70	6	0.79 ± 0.13	0.74 ± 0.09	0.80+0.12
0.70	7	0.81 ± 0.38	0.57 ± 0.27	0.66 ± 0.24

^aIC₅₀ against PCV for the original parental control virus preparation (not passaged in mice). ^bIC₅₀ against PCV ± standard deviation for test isolates for n = 5 samples. ^cIC₅₀ (μgml) PCV for samples 26–30 ranged from 1.09–8.3.